Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Mitochondrial Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRPPRC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRPPRC Recombinant Protein (WT/Truncated) High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW optimized. |
View LRPPRC Products |
| Gene Delivery | LRPPRC Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View LRPPRC Products |
| Benchmark Ab | Anti-LRPPRC Recombinant Antibody Recombinant positive control for ELISA, WB, and IP assays. |
View LRPPRC Products |
| Validator | LRPPRC siRNA Set For specific knockdown verification in functional assays. |
View LRPPRC Products |
| Related Target A | SLIRP (SRA Stem-Loop Interacting RNA Binding Protein) Essential partner protein; forms the LRPPRC-SLIRP complex to regulate mitochondrial mRNA stability. |
View SLIRP Products |
| Related Target B | POLRMT (RNA Polymerase, Mitochondrial) Downstream mitochondrial transcription effector; critical for co-expression and pathway profiling. |
View POLRMT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| LRPPRC molecular weight (~160 kDa) and complex PPR repeats lead to high aggregation risk. | Truncated domain-specific recombinant proteins designed for high solubility and structural stability (>95% purity by SDS-PAGE). |
| Validation of LRPPRC-SLIRP complex disruption by small molecules. | Co-purification grade human LRPPRC and SLIRP proteins strictly verified by mass spectrometry. |
| Lack of reliable intracellular controls for target validation. | Sequence-verified siRNA sets and high-titer Lentivirus for robust knockdown/overexpression in target cell lines. |
| High rate of false positives in binding assays. | HEK293 expressed proteins preserving native post-translational modifications to minimize non-specific interactions. |
Live LRPPRC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRPPRC therapeutics is intensifying, with major players shifting focus from traditional diagnostics to targeting mitochondrial translation and metabolic reprogramming. As first-generation therapies reach the clinic, the next wave of R&D is targeting LRPPRC-SLIRP interface disruption and PROTAC-mediated degradation to overcome drug resistance in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Gastric Cancer, Prostate Cancer | In vitro binding assays (Need high-purity, soluble LRPPRC recombinant proteins) |
| RNA Therapeutics (siRNA/ASO) | Oligonucleotide Therapeutics Developers | Refractory Solid Tumors, Leigh Syndrome Research | In vitro knockdown verification (Need sequence-verified siRNA sets) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Biopharma | Ovarian Cancer, Drug-Resistant Breast Cancer | Target abundance validation (Need high-titer Lentivirus for stable cell line construction) |